SUPPLEMENT
Q3 2020 — Reconciliation of Non-GAAP Financial Measures
Q3 2020PDF · 6 pages189 KB
Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2020 2019 2020 2019 Net Earnings, after tax- as reported $3,554 $1,753 $12,976 $11,109 Pre-tax Adjustments Intangible Asset Amortization expense 1,181 1,138 3,426 3,386 Litigation expense, net 1,477 4,000 2,210 4,832 IPR&D 138 - 144 890 Restructuring related 130 128 363 360 Acquisition and Integration related ¹ (154) 107 (1,087) 229 Unrealized (gains)/losses on securities 32 89 (174) (217) Medical Device Regulation 2 38 - 89 - Other 3 7 6 7 Tax Adjustments Tax impact on special item adjustments 3 (482) (1,159) (1,002) (1,922) Tax legislation and related impacts (49) (391) (483) (391) Adjusted Net Earnings, after tax $5,868 $5,672 $16,468 $18,283 Average shares outstanding (Diluted) 2,669.3 2,669.9 2,670.8 2,688.1 Adjusted net earnings per share (Diluted) $2.20 $2.12 $6.17 $6.80 Operational adjusted net earnings per share (Diluted) $2.17 $6.18 Notes: 1 2 3 Third Quarter Nine Months Ended Acquisition and integration related costs for 2020 primarily includes a Contingent Consideration reversal ($165M in third quarter and $1,148M in nine months) related to the timing of certain developmental milestones associated with the Auris Health acquisition. European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on- going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. -- 1 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical Medical Devices Total WW As Reported 1.3% 5.0% (3.6)% 1.7% U.S. 11.6% 1.5% 1.2% 2.7% International (5.6)% 9.7% (8.1)% 0.6% WW Currency (1.7) 0.4 0.3 0.0 U.S. - - - - International (2.9) 0.9 0.4 0.0 WW Operational 3.0% 4.6% (3.9)% 1.7% U.S. 11.6% 1.5% 1.2% 2.7% International (2.7)% 8.8% (8.5)% 0.6% General Surgery Advanced Sterilization Products 0.5 0.2 U.S. 0.0 0.0 International 0.9 0.4 Baby Care Baby Center 0.1 0.0 U.S. 0.4 0.1 International 0.0 0.0 All Other Acquisitions and Divestitures 0.0 0.1 0.0 0.1 U.S. 0.0 0.0 0.1 0.0 International (0.1) 0.3 0.0 0.1 WW Adjusted Operational 3.1% 4.7% (3.3)% 2.0% U.S. 12.0% 1.5% 1.3% 2.8% International (2.8)% 9.2% (7.6)% 1.1% Adjusted Operational Sales Growth THIRD QUARTER 2020 ACTUAL vs. 2019 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 2 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical Medical Devices Total WW As Reported 1.0% 5.2% (15.3)% (2.0)% U.S. 11.1% 5.2% (15.1)% 0.0% International (6.4)% 5.3% (15.5)% (4.0)% WW Currency (2.4) (0.9) (0.7) (1.2) U.S. - - - - International (4.2) (2.1) (1.4) (2.3) WW Operational 3.4% 6.1% (14.6)% (0.8)% U.S. 11.1% 5.2% (15.1)% 0.0% International (2.2)% 7.4% (14.1)% (1.7)% Skin Health / Beauty Dr. Ci Labo - Japan (0.1) 0.0 U.S. 0.0 0.0 International (0.2) 0.0 General Surgery Advanced Sterilization Products 0.9 0.3 U.S. 0.8 0.3 International 0.9 0.4 Baby Care Baby Center 0.2 0.0 U.S. 0.6 0.1 International 0.0 0.0 All Other Acquisitions and Divestitures (0.1) 0.2 0.0 0.1 U.S. 0.0 0.0 0.0 0.0 International (0.1) 0.3 0.0 0.1 WW Adjusted Operational 3.4% 6.3% (13.7)% (0.4)% U.S. 11.7% 5.2% (14.3)% 0.4% International (2.6)% 7.7% (13.1)% (1.3)% Adjusted Operational Sales Growth NINE MONTHS 2020 ACTUAL vs. 2019 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 3 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 Reported Income Before Tax by Segment $ 191 653 3,439 (222) 1,010 1,392 (239) (176) 4,401 1,647 % to Sales 5.4% 18.8% 30.1% -2.0% 16.4% 21.8% -1.1% -0.8% 20.9% 7.9% Intangible asset amortization expense 104 84 828 809 249 245 - - 1,181 1,138 In-process research and development - - - - 138 - - - 138 - Litigation expense, net 531 (8) 971 3,974 (25) 34 - - 1,477 4,000 Unrealized loss/(gain) on securities (1) 2 31 58 2 29 - - 32 89 Restructuring related 31 17 29 24 70 87 - - 130 128 Acquisition and integration related - - 1 33 (155) 74 - - (154) 107 Medical Device Regulation - - - - 38 - - - 38 - Other - - - - 3 7 - - 3 7 Adjusted Income Before Tax by Segment $ 856 748 5,299 4,676 1,330 1,868 (239) (176) 7,246 7,116 % to Sales 24.4% 21.6% 46.4% 43.0% 21.6% 29.3% -1.1% -0.8% 34.4% 34.3% *Estimated as of 10/13/2020. Q3 QTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 4 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 Reported Income Before Tax by Segment $ 993 1,800 11,787 5,786 2,681 6,078 (611) (554) 14,850 13,110 % to Sales 9.5% 17.4% 35.4% 18.3% 16.4% 31.4% -1.0% -0.9% 24.7% 21.4% Intangible asset amortization expense 306 287 2,378 2,370 742 729 - - 3,426 3,386 In-process research and development - - - 890 144 - - - 144 890 Litigation expense, net 1,169 172 1,006 4,325 35 335 - - 2,210 4,832 Unrealized loss/(gain) on securities - (1) (177) (236) 3 20 - - (174) (217) Restructuring related 69 61 70 68 224 231 - - 363 360 Acquisition and integration related - - 20 123 (1,107) 106 - - (1,087) 229 Medical Device Regulation - - - - 89 - - - 89 - Other - - - - 6 7 - - 6 7 Adjusted Income Before Tax by Segment $ 2,537 2,319 15,084 13,326 2,817 7,506 (611) (554) 19,827 22,597 % to Sales 24.3% 22.4% 45.3% 42.1% 17.2% 38.8% -1.0% -0.9% 33.0% 36.9% *Estimated as of 10/13/2020. Q3 YTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 5 of 6 -- Third Quarter Third Quarter Sept. 27, 2020 GAAP Intangible asset amortization Litigation expense, net Restructuring related Acquisition related (1) Medical Device Regulation Other Sept. 27, 2020 Non-GAAP Cost of products sold 6,972 $ (1,181) (32) (18) 5,741 Selling, marketing and admin expenses 5,431 (4) 5,427 Research and development expense 2,840 5 (16) 2,829 Other (Income) / Expense 1,200 - (1,477) (30) 149 (32) (3) (193) In-process research and development 138 (138) - Restructuring 68 (68) - Provision for taxes on income 847 187 230 29 22 3 5 7 49 (1) 1,378 Net Earnings 3,554 994 1,247 109 108 (157) 27 31 (49) 4 5,868 Third Quarter Third Quarter Sept. 29, 2019 GAAP Intangible asset amortization Litigation expense, net Restructuring related Acquisition related Medical Device Regulation Other Sept. 29, 2019 Non-GAAP Cost of products sold 6,867 $ (1,138) (20) - 5,709 Other (Income) / Expense 4,214 (4,000) (39) (107) (89) (7) (28) Restructuring 69 (69) - Provision for/(Benefit from) taxes on income (106) 127 920 22 19 18 391 53 1,444 Net Earnings 1,753 1,011 3,080 106 88 71 (391) (46) 5,672 Nine Months Nine Months Sept. 27, 2020 GAAP Intangible asset amortization Litigation expense, net Restructuring related Acquisition related (1) Medical Device Regulation Other Sept. 27, 2020 Non-GAAP Cost of products sold 20,613 $ (3,426) (69) (40) 17,078 Selling, marketing and admin expenses 15,627 (10) 15,617 Research and development expense 8,127 - (39) 8,088 Other (Income) / Expense 545 - (2,210) (107) 1,087 174 (6) (517) In-process research and development 144 (144) - Restructuring 187 (187) - Provision for taxes on income 1,874 550 373 30 65 10 (42) 16 483 - 3,359 Net Earnings 12,976 2,876 1,837 114 298 (1,097) (132) 73 (483) 6 16,468 Nine Months Nine Months Sept. 29, 2019 GAAP Intangible asset amortization Litigation expense, net Restructuring related Acquisition related Medical Device Regulation Other Sept. 29, 2019 Non-GAAP Cost of products sold 20,422 $ (3,348) (81) 16,993 Other (Income) / Expense 2,509 (38) (4,832) (117) (229) 217 (7) (2,497) In-process research and development 890 (890) - Restructuring 162 (162) - Provision for taxes on income 2,001 550 1,068 187 63 31 (46) 391 69 4,314 Net Earnings 11,109 2,836 3,764 703 297 198 (171) (391) (62) 18,283 (1) Primarily includes a Contingent Consideration reversal ($165M 2020 quarter to date/$1,148M 2020 year to date) related to the timing of certain developmental milestones associated with the Auris Health acquisition. In-process research and development Unrealized (loss)/gain on securities Tax legislation and related impacts In-process research and development Unrealized (loss)/gain on securities Tax legislation and related impacts Year to Date In-process research and development Unrealized (loss)/gain on securities Tax legislation and related impacts Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date In-process research and development Unrealized (loss)/gain on securities Tax legislation and related impacts -- 6 of 6 --